New diabetes drug shows promise in blood sugar control without weight gain
NCT ID NCT06881264
First seen Jan 29, 2026 · Last updated Jun 10, 2026 · Updated 22 times
Summary
This study tested a new medicine called HR17031 against a standard insulin (insulin glargine) in 401 Chinese adults with type 2 diabetes whose blood sugar was not well controlled with oral medications. The goal was to see if HR17031 could lower blood sugar levels (HbA1c) more effectively and help with weight control. Participants took either HR17031 or insulin glargine for 26 weeks, and researchers measured changes in blood sugar, body weight, and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.